Objective: This study was aimed to evaluate the role of epigallocatechin-3-gallate (EGCG) in the transcriptional regulation of genes associated with migration and inflammation in benign prostate hyperplasia (BPH-1) cells.
 Material and Methods: Effect of EGCG treatment on expressions of FAK, PXN, RhoA, Rac1, Cdc42, PAK1, ROCK1, WASL genes related to migration and IL-8, IL-6, NFκB p50, NFκB p65, IκBα genes related to inflammation were determined by quantitative real time-polymerase chain reaction (qRT-PCR).
 Results: It was determined that EGCG treatment did not significantly change the expressions of investigated genes over 2 fold in terms of mRNA levels. EGCG, which effectively suppresses protein phosphorylations and levels, does not play a role in transcriptional regulation of migration and inflammation-related genes. These results show that EGCG probably reduces the activity of FAK and NFκB signaling pathways by altering the protein function without affecting mRNA levels. 
 Conclusion: It is thought that EGCG may be useful in the treatment of premalignant lesions such as LUTS (lower urinary tract symptoms) and BPH, and its mechanism of action can be predominantly realized at post-translational level.